Chronoscale Holdings Corp quarterly report, Q2 FY2025

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Corp," but the filing text identifies the registrant as Ekso Bionics Holdings, Inc., trading as EKSO).

Reporting Period: Quarterly period ended June 30, 2025 (2025 Q2).

Business Overview: The Company designs, develops, and markets exoskeleton products for healthcare (neurorehabilitation and mobility) and industrial applications. Key products include the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal. The Company operates as a single segment.

Capital Structure Update: A 1-for-15 reverse stock split was effected on June 2, 2025, to regain compliance with Nasdaq minimum bid price requirements. All share and per-share data in this filing reflect this split.

Key Financial Metrics

Metric Q2 2025 (3 Months) Q2 2024 (3 Months) YTD 2025 (6 Months) YTD 2024 (6 Months)
Revenue $2.06 million $4.95 million $5.43 million $8.71 million
Gross Profit $0.82 million $2.64 million $2.63 million $4.59 million
Gross Margin 40% 53% 48% 53%
Net Loss $(2.71) million $(2.42) million $(5.60) million $(5.85) million
Diluted EPS $(1.24) $(1.99) $(3.01) $(4.92)
Cash and Restricted Cash $5.24 million (Balance Sheet Item)
Unrestricted Cash $3.24 million (After $2.0M covenant restriction)
Total Debt (Notes Payable) $4.59 million (Current + Non-current)
Working Capital $9.26 million (Current Assets $15.97M - Current Liab $6.71M)

Material Changes vs. Prior Period

  • Revenue Decline: Revenue decreased 58% in Q2 2025 compared to Q2 2024. This was primarily driven by a decrease in Enterprise Health device sales in the Americas due to delays in closing two large multi-device contracts, expected to close in Q3 2025. This was partially offset by increased Personal Health device sales.
  • Gross Margin Compression: Gross margin declined to 40% in Q2 2025 from 53% in the prior year. Drivers included fixed costs of goods relative to lower Enterprise Health sales volume, lower margin sales through distribution channels, and increased shipping costs.
  • Operating Expenses: Total operating expenses decreased slightly (4%) year-over-year for the quarter. R&D expenses dropped 24% due to lower headcount. G&A expenses increased 12% due to lower allocable manufacturing costs and a $0.18 million impairment loss on an intangible asset (Vanderbilt Knee License Agreement termination).
  • Foreign Exchange Impact: The Company recorded a significant unrealized gain on foreign exchange of $1.34 million in Q2 2025, compared to a loss of $0.09 million in Q2 2024, largely due to the revaluation of inter-company monetary assets and liabilities.
  • Financing Activity: In March 2025, the Company executed a warrant inducement transaction, raising approximately $3.85 million in net proceeds. Additionally, $0.91 million was raised via the At-The-Market (ATM) offering program during the six months ended June 30, 2025.

Guidance, Outlook, Risks, and Contingencies

  • Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for 12 months from the issuance date. Unrestricted cash is estimated to fund operations only into the fourth quarter of 2025. The Company intends to raise funds through one or more financings in the near term.
  • Revenue Outlook: Management expects the majority of 2025 revenue to continue coming from Enterprise Health sales, with Personal Health product sales contributing more quarter-over-quarter. The Company is ramping up CMS reimbursement submissions for the Ekso Indego Personal device.
  • Key Risks:
    • Liquidity: Reliance on external financing to meet material cash requirements.
    • Reimbursement: Dependence on CMS and third-party payor coverage policies for Personal Health product growth.
    • Supply Chain: Potential disruptions and tariff impacts on raw materials and components.
    • Customer Concentration: Three customers accounted for 10% or more of total accounts receivable as of June 30, 2025.
  • Unusual Items: A $0.18 million impairment loss was recognized on an intangible asset following the termination of a license agreement with Vanderbilt University. A $0.23 million deemed dividend was recorded related to the warrant inducement transaction.

Investor Verification Checklist

  • Cash Runway: Verify the timeline and terms of the planned near-term financing required to bridge the gap beyond Q4 2025.
  • Contract Closures: Monitor the status of the delayed Enterprise Health multi-device contracts expected to close in Q3 2025.
  • CMS Reimbursement: Track the volume and approval rate of Ekso Indego Personal reimbursement claims submitted by DME partners.
  • Debt Covenants: Confirm continued compliance with the Banc of California liquidity covenant requiring $2.0 million in restricted cash.
  • Stock Dilution: Assess the impact of outstanding warrants (873,000 shares) and the ATM program ($3.125 million remaining capacity) on future share count.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.